Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia
Hattersley, Andrew T.
© The Author(s) 2013. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Heterozygous glucokinase (GCK) mutations cause mild, fasting hyperglycaemia from birth. Although patients are usually asymptomatic and have glycaemia within target ranges, some are put on pharmacological treatment. We aimed to investigate how many patients are on pharmacological treatment and the impact of treatment on glycaemic control.
European Community’s Seventh Framework Programme
NIHR Exeter Clinical Research Facility
This is a freely-available open access publication. Please cite the published version which is available via the DOI link in this record.
Vol. 57, Issue 1, pp. 54 - 56
FP7/2008-2012 - 223211
Place of publication